Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
- Resource Type
- Article
- Authors
- Arend, Rebecca C.; Monk, Bradley J.; Shapira-Frommer, Ronnie; Haggerty, Ashley F.; Alvarez, Edwin A.; Amit, Amnon; Alvarez Secord, Angeles; Muller, Carolyn; Casado Herraez, Antonio; Herzog, Thomas J.; Tewari, Krishnansu S.; Cohen, Joshua G.; Huang, Marilyn; Yachnin, Adelya; Holeman, Laura L.; Ledermann, Jonathan A.; Rachmilewitz Minei, Tamar; Buyse, Marc; Fain Shmueli, Shifra; Lavi, Michal
- Source
- Journal of Clinical Oncology; 1/10/2024, Vol. 42 Issue 2, p170-179, 15p
- Subject
- Language
- ISSN
- 0732183X